MedWatch

Novo Nordisk uses Genmab platform in hemophilia collaboration

The license agreement, Novo Nordisk and Genmab entered back in 2015, is centered on the development of a new bi-specific antibody against hemophilia. According to CEO in Genmab, Jan van de Winkel, it is a "very differentiated molecule" compared to Roche's Helimbra, which is about cut off billions from Novo's revenue.

Foto: Novo Nordisk

In August 2015, Novo Nordisk and Genmab entered a commercial license agreement allowing Novo to utilize Genmab's DuoBody technology for developing bi-specific antibodies.

Both companies have refrained from commenting on which disease area Novo Nordisk will use the technology within - except that it is outside the cancer area - and Novo Nordisk still keeps its cards close to the chest.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier